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Predictive Value of 18F-Florbetapir and 18F-FDG PET for
Conversion from Mild Cognitive Impairment to Alzheimer
Dementia
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and Philipp T. Meyer1 for the Alzheimer Disease Neuroimaging Initiative
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The present study examined the predictive values of amyloid PET,
18F-FDG PET, and nonimaging predictors (alone and in combination)
for development of Alzheimer dementia (AD) in a large population of
patients with mild cognitive impairment (MCI). Methods: The study
included 319 patients with MCI from the Alzheimer Disease Neuroimaging Initiative database. In a derivation dataset (n 5 159), the
following Cox proportional-hazards models were constructed, each
adjusted for age and sex: amyloid PET using 18F-florbetapir (pattern
expression score of an amyloid-β AD conversion–related pattern,
constructed by principle-components analysis); 18F-FDG PET (pattern expression score of a previously defined 18F-FDG–based AD
conversion–related pattern, constructed by principle-components
analysis); nonimaging (functional activities questionnaire, apolipoprotein E, and mini-mental state examination score); 18F-FDG PET 1
amyloid PET; amyloid PET 1 nonimaging; 18F-FDG PET 1 nonimaging; and amyloid PET 1 18F-FDG PET 1 nonimaging. In a second
step, the results of Cox regressions were applied to a validation
dataset (n 5 160) to stratify subjects according to the predicted
conversion risk. Results: On the basis of the independent validation
dataset, the 18F-FDG PET model yielded a significantly higher predictive value than the amyloid PET model. However, both were inferior to the nonimaging model and were significantly improved by
the addition of nonimaging variables. The best prediction accuracy
was reached by combining 18F-FDG PET, amyloid PET, and nonimaging variables. The combined model yielded 5-y free-of-conversion rates of 100%, 64%, and 24% for the low-, medium- and high-risk
groups, respectively. Conclusion: 18F-FDG PET, amyloid PET, and
nonimaging variables represent complementary predictors of conversion from MCI to AD. Especially in combination, they enable an
accurate stratification of patients according to their conversion risks,
which is of great interest for patient care and clinical trials.
Key Words: mild cognitive impairment; amyloid load; PCA; Cox
model; 18F-florbetapir; 18F-FDG; PET
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DOI: 10.2967/jnumed.119.230797

A

myloid PET using 18F-florbetapir and 18F-FDG PET are
established biomarkers of amyloid-b (Ab) pathology and neuronal
injury in Alzheimer disease, respectively (1). Both modalities
have shown variable performance when adopted to predict progression to Alzheimer dementia (AD) (2,3).
Stratifying mild cognitive impairment (MCI) subjects according
to their conversion risk is of great interest for clinical practice and
clinical trials (e.g., patient counseling, initiation of pharmacologic
and nonpharmacologic treatments, and inclusion in trials). A recent
study by our group evaluated 18F-FDG PET by voxelwise principle-components analysis (PCA) and validated a PCA-derived AD
conversion–related pattern (ADCRP) that showed high accuracy in
prediction of conversion from MCI to AD (4). This study was in
contrast to other studies (5–7). The difference in the results can be
explained by methodology (PCA vs. conventional 18F-FDG PET
analysis) or patient populations (highly selected research vs. real-life clinical population (5)). Conversely, the aforementioned
studies favor amyloid PET over 18F-FDG PET for predicting conversion (5,7).
In the present study, we extended our previous work by also
including amyloid PET and explored the predictive values of 18FFDG PET, amyloid PET, and nonimaging variables, alone and in
combination, in their ability to stratify MCI patients according to
their conversion risk. As in our previous study, we took advantage
of the large patient dataset of the Alzheimer Disease Neuroimaging Initiative (ADNI) database, which enables proper validation by
independent derivation and validation datasets. For a fair comparison
of modalities and in additional to conventional volume-of-interest
analyses (yielding continuous and binary measures of amyloid load),
we also applied voxelwise PCA to the amyloid PET data to assess the
Ab-based ADCRP (Ab-ADCRP).
MATERIALS AND METHODS
Cohort
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The present data were obtained from the ADNI database (ClinicalTrials.gov identifier NCT00106899; further information on the ADNI
project is available at www.adni-info.org). The study was approved by
ADNI, and written informed consent was obtained by the ADNI from
all subjects at the baseline visit (study inclusion) and before protocolspecific procedures were performed, according to the ADNI protocols.
Of the 544 subjects with MCI (suspected incipient Alzheimer disease
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with subjective and objective memory deficits) used in our previous
study (4), we included 319 patients for whom 18F-florbetapir PET at
the baseline visit was also available. Participants were evaluated at
baseline and at 6- to 12-mo intervals after initial evaluation for up to
10 y. The initial inclusion criteria were a diagnosis of MCI, a minimental state examination (MMSE) score of at least 24 points at the
time of PET imaging, a minimal follow-up time of at least 6 mo, and
no bidirectional change of diagnosis (MCI to AD, and back to MCI)
within the follow-up time window. The subjects were dichotomized
into MCI patients who converted to AD (MCI converters) and those
who did not (MCI nonconverters).
The data were randomly split into derivation and validation datasets
(Table 1). Age, sex, MMSE, functional activities questionnaire (FAQ)
sum score, and median follow-up time did not differ significantly
between the 2 datasets (P . 0.1). As would be expected, the prevalence of high-risk apolipoprotein E (APOE) genotypes (3/4 and 4/4)
significantly differed between MCI converters and MCI nonconverters
in each of the datasets (P , 0.01), without evidence of any interaction
between subgroups and datasets (P . 0.1).
PET Analysis

The PET acquisition details have been described in the study
protocols of the ADNI project online. In the case of 18F-FDG PET,
dynamic 3-dimensional scans with six 5-min frames were acquired
30 min after injection of 18F-FDG. All frames were motion-corrected
to the first frame and added into a sum file. 18F-FDG PET scans were
spatially normalized to an in-house 18F-FDG PET template in Montreal Neurological Institute space (8) and smoothed with an isotropic
gaussian kernel of 12 mm in full width at half maximum. We assessed
the pattern expression score (PES) of the previously validated ADCRP
as described before (4).
In the case of 18F-florbetapir PET, dynamic 3-dimensional scans with
four 5-min frames acquired 50–70 min after injection were used for
analysis (details are provided in the ADNI acquisition protocols). Individual datasets were motion-corrected and summed to create singleimage files, followed by spatial normalization to an in-house 18F-florbetapir
PET template in Montreal Neurological Institute space, constructed of
both amyloid-positive (n 5 9) and amyloid-negative (n 5 7) control
scans from cognitively normal elderly people. Smoothing with an
isotropic gaussian kernel of 12 mm in full width at half maximum was

applied. For assessment of amyloid load with 18F-florbetapir PET, we
performed voxelwise PCA on the combined group of MCI converters
and nonconverters from the derivation dataset. To identify a significant
pattern, the best combination of the principal components that account
for maximal variability in the data was selected by a logistic regression
analysis with group (MCI converters and MCI nonconverters) as the
dependent variable and subject score as the independent variable (as
previously described (9)). The obtained Ab-ADCRP represents spatially
covariant voxels associated with the conversion to AD, with each voxel
being specifically weighted toward its relative contribution. For the
derivation and the validation datasets, PES of Ab-ADCRP was evaluated by a topographic profile–rating algorithm (10).
Additionally, we calculated the SUV ratio (SUVR) in regions with
the highest b-amyloid burden in AD (Pittsburgh compound B volumeof-interest mask taken from a previous publication (11)) using the
cerebellum as a reference region, yielding continuous SUVRs. As a
common, clinically used measure, we also defined a binary amyloid
status (0, amyloid-negative; 1, amyloid-positive) based on an SUVR
cutoff of 1.3. All analyses were implemented in an in-house pipeline
based on MATLAB (The MathWorks, Inc.) and Statistical Parametric
Mapping (SPM12) (https://www.fil.ion.ucl.ac.uk/spm/).
Statistical Analysis

For the derivation dataset, Cox proportional-hazards regressions
were calculated using the ‘‘survival’’ package (12) in R (http://www.
R-project.org/), each adjusted for age at baseline (years) and sex. As an
initial step, we compared the 3 outcome measures of amyloid PET
(PES of Ab-ADCRP, continuous SUVR, and binary amyloid status)
by Cox proportional-hazards regression and selected the most predictive measure for further analyses. Subsequently, the predictive accuracy for conversion from MCI to AD was tested for 18F-FDG PET
(PES of ADCRP), amyloid PET (PES of Ab-ADCRP), and nonimaging variables (FAQ, MMSE, and APOE e4 genotype [positive or negative for the presence of at least 1 e4 allele]) separately, both PES of
ADCRP and PES of Ab-ADCRP in combination with nonimaging
variables, and finally all combined in the following models: amyloid
PET (PES of Ab-ADCRP); 18F-FDG PET (PES of ADCRP); nonimaging (FAQ, MMSE, and APOE); 18F-FDG PET 1 amyloid PET;
amyloid PET 1 nonimaging; 18F-FDG PET 1 nonimaging; and
amyloid PET 1 18F-FDG PET 1 nonimaging. Continuous covariates

TABLE 1
Clinical and Demographic Characteristics of Derivation and Validation Datasets
Derivation dataset (n 5 159)
Characteristic
Age (y)

Validation dataset (n 5 160)

MCI converters
(n 5 41)

MCI nonconverters
(n 5 118)

MCI converters
(n 5 33)

MCI nonconverters
(n 5 127)

72 ± 7

73 ± 8

73 ± 8

73 ± 8

Sex (n)
Male

14

55

18

49

Female

27

63

16

111

Mean FAQ ± SD

2.4 ± 3.8

2.7 ± 3.7

2.3 ± 3.5

2.4 ± 3.8

Mean MMSE ± SD

27.8 ± 1.8

27.7 ± 1.8

28.1 ± 1.6

28.1 ± 1.5

APOE ε4–positive rate

78%

49%

90%

40%

Amyloid-positive rate

87%

48%

94%

52%

41

—

37

—

Mean time to conversion (mo)
Follow-up time (mo)
Median
95% confidence interval
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36–51
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were standardized by dividing the individual value by 2 times the SD
of the respective variable to make the variables approximately equally
scaled for appropriate comparison. Because conventional receiveroperating-characteristic analysis does not include time-to-event information, Harrell concordance was used instead to evaluate the goodness
of the fit of the models.
In the validation dataset, the constructed Cox models were validated
by means of offsetting the coefficients evaluated in the derivation dataset. For each model, the change in the Akaike information criterion
(AIC) was computed using the model with the lowest AIC (i.e., best
model) as a reference. Analysis of deviance was conducted for pairwise
comparison between models.
Finally, the prognostic index (PI) (13) for conversion from MCI to
AD was calculated for each subject using the regression coefficients
gained by the respective models on the derivation dataset. Here, the PI
is the sum of the product of the regression coefficients bi and predictor
variables xi (with i being the index for the order of predictors in the
model): PI 5 b1x1 1. . .1 bixi. The PI for each subject was calculated
separately for each model. The validation dataset was stratified into 3
equally sized risk groups based on derived PI values (roughly reflecting the lowest, middle, and highest thirds of the total PI range for each
of the 6 models). Separation between risk groups within different
models was compared by Kaplan–Meier survival analysis. Interpretability of risk strata was limited after 60 mo by the small number of
subjects with such long observation times. Thus, the display of the
results (but not the statistical analysis) was restricted to a follow-up
interval of 60 mo.
RESULTS
Aβ-ADCRP

Scaled subprofile model PCA analysis identified 2 significant
principal components (1 and 2) that accounted for a total of 37%
variability in the data. The logistic regression model including
these principal components yielded the highest significance and
lowest AIC compared with principal component 1 or 2 alone; therefore, they were linearly combined to construct the Ab-ADCRP
(Fig. 1A), which allows for a highly significant separation between

MCI converters and nonconverters (P 5 2 · 10212). The regions
with the highest positive voxel loads (elevated amyloid load) include the posterior cingulate cortex and precuneus, the mesial frontal cortex, the insular region, the ventral striatum, and, to a slightly
lesser extent, the lateral frontal, temporal, and parietal cortices.
For comparison, Figure 1B displays the previously defined 18FFDG PET–based ADCRP (4), which showed prominent negative
voxel loads (regional hypometabolism) in MCI converters compared with nonconverters in the temporoparietal cortex and in the
posterior cingulate cortex and precuneus.
Derivation Dataset

The Cox proportional-hazards regression constructed with different measures of amyloid load based on 18F-florbetapir PET was
penalized for multicollinearity among predictors and identified PES
of Ab-ADCRP to have a higher hazard ratio (3.1, P , 0.002) than
continuous SUVR (hazard ratio, 1.7; P 5 0.09) or binary amyloid
status (hazard ratio, 1.4; P 5 0.33). Therefore, PES of Ab-ADCRP
was used as a measure of amyloid load in all subsequent analyses.
Model characteristics and comparisons are summarized in Supplemental Table 1 (supplemental materials are available at http://jnm.
snmjournals.org). Because we observed significant, although weak,
correlations between PES of ADCRP and PES of Ab-ADCRP
(r 5 0.33, P , 0.001), PES of ADCRP and MMSE, FAQ, and APOE
(r 5 20.22, P 5 0.003; r 5 0.24, P 5 0.002; and r 5 0.23, P 5
0.003, respectively), and PES of Ab-ADCRP and MMSE, FAQ, and
APOE (r 5 20.22, P 5 0.005; r 5 0.28, P , 0.001; and r 5 0.47,
P , 0.001, respectively), the models were computed using the ridge
regression option to account for multicollinearity. Both the 18F-FDG
PET and the amyloid PET models significantly predicted conversion
to AD (both P , 0.001). The combined amyloid PET 1 18F-FDG
PET 1 nonimaging model showed the highest concordance (Harrell
concordance, 0.87; P , 0.001) among constructed models.
Validation Dataset

The constructed Cox models were applied to the validation
dataset (Table 2). Comparisons were done in 3 sequential steps, in
which the most accurate model of the previous step served as the basis for more comprehensive models in subsequent steps (age
and sex served as baseline variables). Change
in AIC (DAIC) was calculated with reference
to the model including both imaging and the
nonimaging variables because this model
yielded the lowest overall AIC (270.0).
Step 1. The 18F-FDG PET model (DAIC,
23.9) was significantly (P , 0.001) better
than the amyloid PET model (DAIC, 25.9).
However, the nonimaging model showed a
significantly lower AIC (DAIC, 19.7) than
either the 18F-FDG PET model (P , 0.005)
or the amyloid PET model (P , 0.005).
Step 2. The 18F-FDG PET 1 nonimaging model (DAIC, 8.5) and the amyloid
PET 1 nonimaging model (DAIC, 8.9)
FIGURE 1. ADCRPs of amyloid binding and glucose metabolism. (A) Aβ-ADCRP derived by
constituted significant improvements (P ,
PCA on 18F-florbetapir PET data. (B) ADCRP derived by PCA on 18F-FDG PET data. Voxels with
0.001) over the nonimaging model alone,
negative region weights (coded as z score) are given in cool colors, and regions with positive
with the former performing significantly
region weights are depicted in warm colors. Data on neurologic orientation (i.e., left image side
better than the latter (P , 0.01).
corresponds to patients’ left body side) are presented. Regions with increased amyloid load (A)
Step 3. The complementary predictive
and decreased metabolism (B) show positive and negative weights, respectively, whereas relavalue of the aforementioned variables is
tively spared regions are loaded with opposite weights due to data normalization.
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TABLE 2
Comparison of Cox Predictive Models: Validation Dataset
Step
1

2

Model 1

Model 2

DAIC model 2

P*
0.001

Amyloid PET

25.9

Nonimaging

19.7

18F-FDG

PET

23.9

Nonimaging

19.7

0.004

Amyloid PET

25.9

18F-FDG

23.9

5 · 10−4

Nonimaging

19.7

Amyloid PET 1 nonimaging

8.9

1 · 10−4

Nonimaging

19.7

18F-FDG

PET 1 nonimaging

8.5

8 · 10−5

8.9

18F-FDG

PET 1 nonimaging

8.5

0.008

PET

23.9

18F-FDG

PET 1 amyloid PET

10.7

2 · 10−5

Amyloid PET

25.9

18F-FDG

PET 1 amyloid PET

10.7

9 · 10−6

10.7

Amyloid PET 1

18F-FDG

PET 1 nonimaging

0

1 · 10−4

8.9

Amyloid PET 1

18F-FDG

PET 1 nonimaging

0

2 · 10−4

8.5

Amyloid PET 1

18F-FDG

PET1 nonimaging

0

4 · 10−4

Amyloid PET 1 nonimaging
18F-FDG

3

DAIC model 1

18F-FDG

PET 1 amyloid PET

Amyloid PET 1 nonimaging
18F-FDG

PET 1 nonimaging

PET

*Improvement in goodness of fit from models 1 to 2 (validation dataset).
DAIC is with reference to amyloid PET 1 18F-FDG PET 1 nonimaging model that reached lowest AIC of all models (270.0).

underlined by the combined amyloid PET 1 18F-FDG PET 1
nonimaging model, which yielded the lowest AIC and was significantly superior to the 18F-FDG PET 1 nonimaging model (P ,
0.001). For reasons of comprehensiveness, Table 2 also lists additional possible comparisons.
Conversion Analysis

Each of the 6 constructed models was also applied to the
validation dataset to calculate the individual PI for each
subject and model. The resulting Kaplan–Meier plots are shown
in Figure 2. Five-year free-of-conversion rates for the low-,
medium- and high-risk groups and their comparisons are summarized in Table 3. The 18F-FDG PET and amyloid PET models
showed significant (P , 0.05) strata separation only for the
high-risk group and the low-risk group, respectively, whereas
the nonimaging and the combined models showed significant
separations between all 3 groups (P , 0.05) (Fig. 2). The strata
separation was slightly better for the 18F-FDG PET 1 nonimaging model than for the amyloid PET 1 nonimaging model (Table
3; Fig. 2). However, the benefit of combining all the variables for
risk group stratification was actually small based on Kaplan–
Meier curves (Figs. 2E and 2F), although the amyloid PET 1
18 F-FDG PET 1 nonimaging model performed significantly
better (P , 0.001) than the 18F-FDG PET 1 nonimaging model
(Table 2).
DISCUSSION

In a large cohort of subjects, 18F-FDG PET and 18F-florbetapir
PET in combination with voxel-based PCA and nonimaging variables predicted conversion from MCI to AD. Interestingly, 18FFDG PET outperformed amyloid PET in prediction accuracy, and
the nonimaging model (including APOE, FAQ, and MMSE) was
superior to both imaging models. Still, the nonimaging model was
improved by adding amyloid data and (even more so) 18F-FDG
PET data, and the model including amyloid PET, 18F-FDG PET,
and nonimaging variables yielded the highest prediction accuracy,
underscoring their complementary value. The only single-component model that allowed for significant separation between all
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3 risk groups was the nonimaging model, whereas the best separation between risk strata was achieved by combining predictor
variables.
To improve comparability between 18F-FDG and amyloid
PET, a sophisticated method based on voxelwise PCA was applied to 18F-florbetapir PET data. The obtained network topography is consistent with previously published typical regions of
amyloid deposition in AD (11,14), although it revealed some
regions with unexpectedly high weighting (e.g., insular region).
Interestingly, we found that the PES of Ab-ADCRP and the PES
of the 18F-FDG PET–based ADCRP showed comparably high
correlations with MMSE and FAQ in the present sample of
MCI patients. Finally, we demonstrated that prediction of conversion based on Ab-ADCRP was superior to conventional amyloid PET analyses (i.e., continuous SUVR in AD-typical regions
and binary amyloid status). Taken together, this finding strongly
supports future exploration and possible clinical use of the AbADCRP.
Our finding that amyloid PET predicts development of AD is in
line with several studies (5,15,16), with Schreiber et al. (15) and
Ben Bouallègue et al. (16) contemplating an overlapping ADNI
cohort. Previous studies compared predictive values of amyloid
PET and 18F-FDG PET in smaller patient samples: Brück et al.
(17) reported similar predictive accuracies for 18F-FDG and amyloid PET, whereas Frings et al. (5) and Trzepacz et al. (7) reported amyloid PET to be a better predictor (18F-FDG PET being not
even a significant predictor in the study of Frings et al. (5)). In the
present study, 18F-FDG PET was slightly superior to amyloid PET in
predicting conversion, as is in line with a study by Prestia et al.
(18), who described 18F-FDG PET as the best predictor of progression from MCI to AD among various biomarkers, including
Ab42 in cerebrospinal fluid. Variable results may be explained by
different methodologies or patient populations.
The combined set of nonimaging variables more accurately
predicted the conversion from MCI to AD than either 18F-FDG
or amyloid PET. This effect was driven by the particularly high
predictive value of the FAQ (4), probably because the clinical
decision on dementia is highly influenced by impairment of activities

NUCLEAR MEDICINE • Vol. 61 • No. 4 • April 2020

FIGURE 2. Kaplan–Meier curves of validation dataset. Risk strata using PI are based on amyloid PET model (A), 18F-FDG PET model (B), nonimaging model (C), amyloid PET 1 nonimaging model (D), 18F-FDG PET 1 nonimaging model (E), and amyloid PET 1 18F-FDG PET 1 nonimaging
model (F).

of daily living, which FAQ assesses. Moreover, the predictive accuracy of nonimaging variables was improved by adding 18F-FDG and
amyloid PET, alone or in combination, underlining their complementary value.
Part of the validation dataset of the current study (n 5 81) is a
subset of the derivation dataset (n 5 272) of our previous 18FFDG PET study (4), in which the ADCRP was established.

Nonetheless, exclusion of these subjects in the current validation
dataset did not relevantly change the results. In turn, and in
contrast to the validation dataset, the amyloid PET model performed slightly better than the 18F-FDG PET model on the derivation dataset (Supplemental Table 1), which, however, might
well be explained by the fact that the Ab-ADCRP was defined on
this dataset.

TABLE 3
Separation of Risk Strata by Different Models in Validation Dataset
5-y free-of-conversion
rate
Parameter

Pairwise log-rank P

Low

Medium

High

Medium vs. high

Low vs. medium

Low vs. high

Amyloid PET

98%

54%

55%

0.331

1 · 10−4

1 · 10−5

18F-FDG

79%

76%

45%

0.022

0.109

6 · 10−4

PET

Nonimaging
18F-FDG

PET 1 amyloid PET

Amyloid PET 1 nonimaging
18F-FDG

PET 1 nonimaging

Amyloid PET 1

18F-FDG

PET 1 nonimaging

95%

54%

40%

1 · 10−4

0.032

7 · 10−8

97%

70%

33%

1 · 10−4

0.008

2 · 10−8

39%

1·

10−5

0.015

8 · 10−9

10−6

0.003

1 · 10−10

0.002

5 · 10−11

97%

63%

100%

74%

19%

8·

100%

64%

24%

4 · 10−6
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With this large cohort of subjects with long follow-up times
(median follow-up based on inverse Kaplan–Meier method, 48 mo
[95% confidence interval, 35–52 mo]), we demonstrated the benefit of combining available imaging and nonimaging information into a single quantifiable PI of conversion for each subject.
The combination of imaging and nonimaging variables gave the
best predictive accuracy, which is similar to the study by Ben
Bouallègue et al. (16). The separation between risk groups increases significantly when imaging variables (amyloid PET and,
even more, 18F-FDG PET) are combined with nonimaging variables
into a single model or when both imaging variables are combined
together.
Biomarkers of neurodegeneration derived from modalities other
than 18F-FDG PET have also been shown to predict time to conversion from MCI to AD, especially MRI-based biomarkers (19)
and cerebrospinal fluid total tau concentration (1). In this study, no
comparison was performed against alternative neurodegenerative
markers, and further studies are needed to compare the predictive
powers of these biomarkers.
Although both 18F-FDG PET and amyloid PET were available
for each ADNI patient analyzed in the present study, such is often
not the case in clinical routine. We have shown that the combination of 18F-FDG PET and nonimaging variables is superior to the
combination of amyloid PET and nonimaging variables. Furthermore, the risk stratification was fairly comparable between the
18F-FDG PET 1 nonimaging model, the 18F-FDG PET 1 amyloid
PET model, and the model combining all 3 sets of variables,
although this last model performed significantly better. Aside from
lower costs and wider availability, an additional strength of 18FFDG PET over amyloid PET may be the detection of neurodegenerative causes of MCI that are not associated with brain amyloidosis
(20,21). Thus, further prospective studies on larger patient samples
are warranted to define the predictive value and cost effectiveness of
the present imaging and nonimaging variables (alone and in combination) in clinical routine.
CONCLUSION
18F-FDG PET, amyloid PET, and nonimaging variables represent complementary predictors of conversion from MCI to AD.
The PES of the ADCRP (18F-FDG PET) yielded higher predictive
accuracy than the PES of Ab-ADCRP (18F-florbetapir PET). The
combination of imaging and nonimaging variables enables accurate stratification of patients according to their conversion risk,
which is of great interest for clinical practice and clinical trials.
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KEY POINTS
QUESTION: What are the predictive values of amyloid PET
with 18F-florbetapir, 18F-FDG PET, and nonimaging predictors
(APOE, FAQ, and MMSE) for development of AD in patients
with MCI?
PERTINENT FINDINGS: In a large sample of patients with MCI
(n 5 319 from ADNI, split into a derivation and a validation dataset)
and ADCRPs identified by PCA, we demonstrated that 18F-FDG
PET, amyloid PET, and nonimaging variables represent complementary predictors of conversion from MCI to AD. 18F-FDG PET
yielded higher predictive accuracy than amyloid PET (each alone
and in combination with nonimaging variables). Using a PI and
Kaplan–Meier analyses, we found that risk group separation was
slightly better for the 18F-FDG PET 1 nonimaging model than for
the amyloid PET 1 nonimaging model. The additional benefit of
combining all the variables for risk group stratification was actually
small, although the combination of all variables performed significantly better than the 18F-FDG PET 1 nonimaging model.
IMPLICATIONS FOR PATIENT CARE: PCA analyses of 18F-FDG
and amyloid PET data and nonimaging variables represent complementary predictors for stratifying MCI subjects according to
their conversion risk, which is of great interest for clinical practice
and clinical trials (e.g., patient counseling, initiation of pharmacologic and nonpharmacologic treatments, and inclusion in
trials).
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